000 02298cam  2200397zi 4500
006m     o  d f      
007cr mn|||||||||
008220620t19831983onca    ob   f000 0 eng d
020 |a0662525329 |q(bilingual ; |qprint)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aRG15-2/1983E-PDF
0861 |aRG15-2/1983-PDF
24500|aCompulsory licensing of pharmaceuticals : |ba review of Section 41 of the Patent Act.
264 1|a[Ottawa] : |bConsumer and Corporate Affairs Canada = Consommation et corporations Canada, |c1983.
264 4|c©1983
300 |a1 online resource (ix, 64 pages) : |billustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Octroi obligatoire de licences dans le domaine des produits pharmaceutiques : révision de l'article 41 de la Loi sur les brevets.
500 |a"June 1983."
500 |aDigitized edition from print [produced by Innovation, Science and Economic Development Canada].
504 |aIncludes bibliographical references.
520 |a"This paper reviews the effect of the 1969 Patent Act revisions on the drug industry in Canada. It analyzes how these changes have affected the activities of the pharmaceutical industry, the prices of prescription drugs and the current investment climate in Canada. It also considers, in line with government policy to stimulate high technology industry, a number of possible changes to the Patent Act that may improve the investment climate for major pharmaceutical firms while assuring a continued supply of reasonably priced drugs for Canadians"--Introduction, page 1.
61010|aCanada. |tPatent Act.
650 0|aPharmaceutical industry|zCanada.
650 0|aDrugs|xPrices|zCanada.
650 0|aCompulsory licensing of patents|zCanada.
7101 |aCanada. |bConsumer and Corporate Affairs Canada, |eissuing body.
77508|tOctroi obligatoire de licences dans le domaine des produits pharmaceutiques : |w(CaOODSP)9.912487
85640|qPDF|s4.24 MB|uhttps://publications.gc.ca/collections/collection_2022/isde-ised/RG15-2-1983-eng.pdf